Sinovac reports back on preliminary COVID-19 vaccine study

Organisation: Position: Deadline Date: Location:

Sinovac Biotech has announced preliminary study results showing its experimental COVID-19 vaccine generated immune responses in patients and was safe – early data that suggest it might protect people against infections with the novel coronavirus.

Stat News reports that the Beijing-based drug maker’s vaccine, called CoronaVac, induced neutralising antibodies in “above 90%” of people who were tested 14 days after receiving two injections, two weeks apart. There were no severe side effects reported, the company said in a statement.

The preliminary results were from a 600-patient, placebo-controlled Phase 2 study. Sinovac is also conducting a 143-patient, placebo-controlled Phase 1 study.

The report says there are currently more than two dozen research efforts underway to develop protective vaccines against the novel coronavirus that causes COVID-19.

In May, Moderna, a Cambridge, Massachusetts-based biotech firm, announced early and encouraging immune-response results for its experimental COVID-19 vaccine – although vaccine experts criticised the company for not disclosing enough detailed data.

The report says in similar ways, Sinovac’s statement was short on details about the extent of CoronaVac’s efficacy and safety. The company said it expects to submit a report on the Phase 2 study results in the “near future,” at the same time as it submits a design protocol for a Phase 3 clinical trial to China’s version of the Food and Drug Administration.

Earlier this week, Sinovac also announced a collaboration with a Brazilian drug maker to start a Phase 3 clinical study there.

“Our phase 1/2 study shows CoronaVac is safe and can induce immune response,” Sinovac CEO Weidong Yin is quoted in the report as saying. Sinovac is building a manufacturing facility intended to “maximise the number of doses available to protect people from COVID-19,” he added.

Sinovc’s CoronaVac vaccine candidate uses an inactivated version of the novel coronavirus. The company used the same technology to craft approved vaccines for hepatitis A and B; swine flu; avian flu; and the virus that causes hand, foot, and mouth disease.


Full Stat News report

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.